MGI Pharma received approval from the FDA for Dacogen for the treatment of adult patients with myelodysplastic syndromes (MDS). This new drug to combat MDS is the first high potency new chemical entity (NCE) which was developed and produced by fee-for-service provider Ferro Pfanstiehl Laboratories, Inc. Ferro Pfanstiehl provided API development, validation, clinical trial material and commercial production of Dacogen for Injection. “This success validates Ferro Pfanstiel’s fores...